Federal Register #2026-15906

CDC Awards for Global and African Influenza Surveillance and Response Services

This award announcement details the Centers for Disease Control and Prevention (CDC)'s cooperative agreements to support global and African regional pandemic and influenza surveillance and response. - Government Buyer: - Centers for Disease Control and Prevention (CDC) - National Center for Immunization and Respiratory Diseases - Global Influenza Branch - OEMs and Vendors: - The Task Force for Global Health, Inc. (primary awardee for global coordination) - Multiple national health institutes and universities in Africa (recipients of regional awards) - Products/Services Requested: - Services to strengthen surveillance, early detection, prevention, and response for pandemic and novel influenza, as well as other infectious disease threats - Coordination of global influenza prevention and control efforts, including public-private partnerships and support for vaccine programs - Capacity building for data sharing, epidemic readiness, and evidence-based interventions - Unique or Notable Requirements: - Emphasis on global and regional coordination for influenza and respiratory virus surveillance - Focus on building and maintaining surveillance and response capacity in Africa - No specific products or part numbers; all awards are for public health services and programmatic support - Activities include strategic information gathering, implementation of interventions, and support for vaccine initiatives

Description

The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces a single source cooperative agreement award to fund The Task Force for Global Health. The award is approximately $4,000,000 for Federal Fiscal Year 2026, subject to the availability of funds, with funding for years 2-5 set at continuation. The purpose of the award is to support surveillance and response for pandemic and novel influenza and other infectious disease threats worldwide. The period of performance is from September 30, 2026, through September 29, 2031.

View original listing